The content on this site is intended for healthcare professionals only
Prof Gunter Von Minckwitz talks to ecancer about assessing neoadjuvant therapy in breast cancer and recent developments at IMPAKT 2012 in Brussels, May 2012.
Recent developments have allowed patients to benefit by receiving better treatment through more accurate prognostics on the subtype of their tumour. There are now a series of trials that show an increase of complete pathological response in patients with HER2+ tumours.
Filming Supported by Amgen
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
GIST tumours and soft tissue sarcomas
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer
EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Overview of the management of HER2-low breast cancer patients
